The Chemours Company filings document formal disclosures for a NYSE-listed global chemistry company with businesses in Thermal & Specialized Solutions, Titanium Technologies, and Advanced Performance Materials. Recent Form 8-K reports furnish operating results and financial condition updates, including segment commentary on Opteon refrigerants, TiO2 pigment, and other specialty-chemistry markets.
Regulatory filings also cover capital-structure actions, including senior unsecured notes, indentures, guarantees, and redemption of outstanding debt. Definitive proxy materials document board structure, director elections, advisory compensation votes, auditor ratification, equity-incentive plan approval, and other shareholder voting matters.
Chemours Co/The — The Vanguard Group filed Amendment No. 11 to its Schedule 13G/A reporting beneficial ownership of 0 shares (0%) of Chemours common stock. The filing states that an internal realignment effective January 12, 2026 caused certain Vanguard subsidiaries/divisions to report holdings separately in reliance on SEC Release No. 34-39538.
The filing is signed by Ashley Grim, Head of Global Fund Administration on 03/26/2026 and lists Vanguard's principal business office in Malvern, Pennsylvania.
The Chemours Company completed a private Offering of $700,000,000 aggregate principal amount of 7.875% senior unsecured notes due 2034. The notes were sold to qualified institutional buyers and are senior unsecured obligations guaranteed by a subsidiary.
Chemours used the net proceeds, together with cash on hand, to redeem $188,000,000 of 5.750% senior notes due 2028 for an aggregate redemption price of about $189,800,000 plus interest. The remaining net proceeds are expected to fund the redemption of 5.375% senior notes due 2027 for an aggregate redemption price of about $500,300,000, plus accrued interest.
The Chemours Company is asking shareholders to elect eleven directors and approve several governance and compensation proposals at its virtual 2026 annual meeting on April 24, 2026. Items include director elections, an advisory vote on executive pay, a new 2026 Equity and Incentive Plan, and auditor ratification.
The proxy highlights Chemours’ Pathway to Thrive strategy, focused on operational excellence, growth in areas like semiconductors and data centers, portfolio simplification, and long-term risk reduction. In 2025, the company delivered $5.8 billion in net sales, $742 million in Adjusted EBITDA and returned $78 million in dividends, while recording a net loss of $386 million largely due to litigation-related charges.
Board oversight features an independent chair, lead independent director, fully independent committees and strong risk, cybersecurity and sustainability governance. Since 2018, Chemours reports a 76% reduction in fluorinated organic chemical process emissions and a 52% cut in Scope 1 and 2 greenhouse gas emissions, supporting its Trusted Chemistry and 2030 responsibility goals.
Chemours senior vice president Kristine M. Wellman reported equity compensation and related tax withholding transactions in company common stock. She received a grant of 25,708 restricted stock units, which are scheduled to vest in three equal annual installments beginning on March 1, 2027. To cover tax obligations from previously vesting RSUs and dividend equivalent units, 3,359 shares were automatically withheld at a price of $18.24 per share, and the disclosure states that no shares were sold in the market. After these changes, she reports direct ownership of 73,750.6057 shares, RSUs, and dividend equivalent units in total.
Chemours executive Gerardo Familiar Calderon reported equity compensation changes involving company common stock. He received a grant of 25,708 shares of common stock at a price of $0.0000 per share as a grant, award, or other acquisition, structured as restricted stock units and related dividend equivalent units.
Separately, 2,635 shares were automatically withheld at $18.24 per share to satisfy tax obligations upon vesting of existing restricted stock units; footnotes state that no shares were sold and the transaction is exempt under Rule 16b-3. The new RSU award is scheduled to vest in three equal annual installments beginning on March 1, 2027, and the reported holdings include directly owned shares, RSUs, and dividend equivalent units.
Chemours Chief Executive Officer Denise Dignam reported equity compensation changes. She received a grant of 169,538 shares of common stock at $0.00 per share, in the form of restricted stock units scheduled to vest in three equal annual installments beginning on March 1, 2027. To satisfy tax obligations on vesting RSUs and related dividend equivalent units, 22,220 shares were automatically withheld at $18.24 per share; the company notes no shares were sold in the market. Following these transactions, she directly holds 335,313.8721 shares, including RSUs and dividend equivalent units.
Chemours Co reported that officer Michael Robert Foley acquired two grants of common stock in the form of restricted stock units. One award covers 25,013 RSUs that vest in three equal annual installments beginning on March 1, 2027, and another covers 50,027 RSUs scheduled to vest on March 1, 2029. Following these awards, Foley directly holds or is credited with 78,540 Chemours equity units, including directly owned shares, RSUs and related dividend equivalent units.
Chemours officer Joseph T. Martinko reported two stock transactions involving company common shares. On March 2, 2026, he acquired 28,488 shares at $0.00 per share through a grant classified as a grant, award, or other acquisition. On March 1, 2026, 2,789 shares at $18.24 per share were automatically withheld to cover tax obligations tied to vesting restricted stock units and related dividend equivalent units, and the footnote clarifies that no shares were sold on the market. After these transactions, his directly held and unit-based interests total 53,889.1669 shares, including common stock, restricted stock units, and dividend equivalent units. The RSU grant is scheduled to vest in three equal annual installments beginning on March 1, 2027, providing a staged equity-based compensation stream over time.
Chemours Chief Financial Officer Shane Hostetter reported equity compensation and related tax withholding transactions in company common stock. On March 2, he acquired 47,387 shares through a grant or award at a stated price of $0.0000 per share, increasing his directly owned and unit-based holdings to 101,857.1999 shares. A related footnote states this restricted stock unit (RSU) award is scheduled to vest in three equal annual installments beginning on March 1, 2027. On March 1, 3,232 shares at $18.2400 per share were automatically withheld to satisfy tax obligations on vesting RSUs and dividend equivalent units, with the filing clarifying that no shares were sold. Following the tax-withholding disposition, his directly held total was 54,470.1999 shares, which a footnote explains includes directly owned shares, RSUs and dividend equivalent units.